FDA Grants Breakthrough Therapy Designation to Gene Therapy for Treatment of CALD – Rare Disease Report
Rare Disease Report |
FDA Grants Breakthrough Therapy Designation to Gene Therapy for Treatment of CALD
Rare Disease Report The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to bluebird bio, Inc.’s Lenti-D, a gene therapy for patients with cerebral adrenoleukodystrophy (CALD), a serious X-linked genetic disease that is rare and … |
CNBC |
AstraZeneca CEO on immunotherapy, drug prices
CNBC AstraZeneca CEO on immunotherapy, drug prices. 34 Mins Ago. Pascal Soriot, AstraZeneca CEO, speaks to CNBC’s Meg Tirrell at American Society of Clinical Oncology (ASCO) conference about the company’s immunotherapy treatments, research and … |
|
New gene therapy technique could reverse Alzheimer’s
Barchester Healthcare (blog) Scientists at the Massachusetts Institute of Technology (MIT) have found a way to render the gene responsible for Alzheimer’s disease harmless. By using a genetic snipping technique, APOE4, which causes amyloid beta proteins in the brain to build up … |
UT News | The University of Texas at Austin |
A Change in Bacteria’s Genetic Code Holds Promise of Longer-Lasting Drugs
UT News | The University of Texas at Austin “We have been able to expand the genetic code to make new, biomedically relevant proteins,” said Andrew Ellington, associate director of the Center for Systems and Synthetic Biology and a professor of molecular biosciences who co-authored the study. |
pharmaphorum |
ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR …
pharmaphorum The American Society of Clinical Oncology (ASCO) has already singled out CAR-T therapies as the most promising advance in cancer therapy this year – and … Celgene (CELG), bluebird bio (BLUE) Phase I Study of bb2121 …StreetInsider.com |
pharmaphorum |
ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR …
pharmaphorum The American Society of Clinical Oncology (ASCO) has already singled out CAR-T therapies as the most promising advance in cancer therapy this year – and … Celgene (CELG), bluebird bio (BLUE) Phase I Study of bb2121 …StreetInsider.com |
Bloomberg |
Billions of T–Cells Clear Woman’s Breast Cancer in Study
Bloomberg The immunotherapy field has seen major breakthroughs in the past year, including the approval of two so-called CAR-T treatments from Gilead and Novartis AG that extract T–cells from a patient’s blood and re-engineer them to recognize malignancies. New Immunotherapy Treatment Removes All Tumors In Woman With Advanced Metastatic Breast CancerForbes In a first, scientists use immunotherapy to rid patient of advanced breast cancerLos Angeles Times |